{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:50:22Z","timestamp":1777420222841,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective was to evaluate the efficacy\/safety of pirtobrutinib in the treatment of B-cell malignancies and distinguish it from other available Bruton\u2019s tyrosine kinase (BTK) inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>A literature search of PubMed (January 2021 through November 2023) and Clinicaltrials.gov was conducted using terms pirtobrutinib, Jaypirca, and LOXO 305. Licensing trials of available BTK inhibitors were also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>Relevant English-language clinical trials were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>Pirtobrutinib was approved by the US Food and Drug Administration for the treatment of relapsed\/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) based largely on a phase 1\/2 study in B-cell malignancies. Pirtobrutinib demonstrated a 73% overall response rate (ORR) in the CLL population and 58% in MCL. Pirtobrutinib has activity in patients resistant to earlier-generation, covalent BTK inhibitors. In fact, the ORRs were similar in BTK-pretreated and na\u00efve patients. Adverse effects include fatigue, diarrhea, bleeding, and infection. Atrial fibrillation, a class effect of BTK inhibitors, may be less common with pirtobrutinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice in comparison with existing drugs:<\/jats:title>\n                    <jats:p>Compared with earlier-generation BTK inhibitors, pirtobrutinib is more selective for BTK and binds noncovalently to the receptor. Ongoing studies are evaluating pirtobrutinib\u2019s use in multiple B-cell malignancies and comparing it with other BTK inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The characteristics of pirtobrutinib render it useful in the treatment of B-cell malignancies no longer responding to a previous BTK inhibitor, and results from ongoing clinical trials may support future expanded use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231223737","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T06:53:48Z","timestamp":1705560828000},"page":"1064-1073","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies"],"prefix":"10.1177","volume":"58","author":[{"given":"Madeline D.","family":"Schultze","sequence":"first","affiliation":[{"name":"College of Pharmacy & Health Sciences, Butler University, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-096X","authenticated-orcid":false,"given":"David J.","family":"Reeves","sequence":"additional","affiliation":[{"name":"College of Pharmacy & Health Sciences, Butler University, Indianapolis, IN, USA"},{"name":"Franciscan Health Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"bibr1-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00857-8"},{"key":"bibr2-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00675-9"},{"key":"bibr3-10600280231223737","unstructured":"Jaypirca (Pirtobrutinib) [package insert]. Eli Lilly and Company; 2023."},{"key":"bibr4-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"bibr5-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"bibr6-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00562"},{"key":"bibr7-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"bibr8-10600280231223737","unstructured":"Imbruvica (Ibrutinib) [package insert]. Pharmacyclics, LLC; 2023."},{"key":"bibr9-10600280231223737","unstructured":"Calquence (Acalabrutinib) [package insert]. AstraZeneca Pharmaceuticals LP; 2022."},{"key":"bibr10-10600280231223737","unstructured":"Brukinsa (Zanubrutinib) [package insert]. BeiGene USA, Inc; 2023."},{"key":"bibr11-10600280231223737","unstructured":"Eli Lilly and Company (Loxo Oncology, Inc.). Study of LOXO-305 Versus Investigator\u2019s Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic (CLL)\/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321) (NCT466038). ClinicalTrials.gov; 2023. Accessed October 1, 2023. https:\/\/clinicaltrials.gov\/study\/NCT04666038"},{"key":"bibr12-10600280231223737","unstructured":"Eli Lilly and Company (Loxo Oncology, Inc.). Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-314) (NCT05254743). Clinicaltrials.gov; 2023. Accessed October 1, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05254743"},{"key":"bibr13-10600280231223737","unstructured":"Eli Lilly and Company (Loxo Oncology, Inc.). Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313) (NCT05023980). Clinicaltrials.gov;2023. Accessed October 1, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05023980"},{"key":"bibr14-10600280231223737","unstructured":"Eli Lilly and Company (Loxo Oncology, Inc.). A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia\/ Small Lymphocytic Lymphoma (CLL\/ SLL) (BRUIN CLL-322) (NCT04965493). Clinicaltrials.gov; 2023. Accessed October 1, 2023. https:\/\/clinicaltrials.gov\/study\/NCT04965493."},{"key":"bibr15-10600280231223737","unstructured":"Eli Lilly and Company (Loxo Oncology, Inc.). Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321) (NCT04662255). Clinicaltrials.gov; 2023. Accessed October 1, 2023. https:\/\/clinicaltrials.gov\/study\/NCT04662255"},{"key":"bibr16-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"bibr17-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"bibr18-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"bibr19-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"bibr20-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818"},{"key":"bibr21-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"bibr22-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801"},{"key":"bibr23-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01485-x"},{"key":"bibr24-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"bibr25-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000118"},{"key":"bibr26-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001678"},{"key":"bibr27-10600280231223737","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections (Version 2.2023). Accessed December 6, 2023. www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf"},{"key":"bibr28-10600280231223737","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas (Version 6.2023). Accessed October 10, 2023. www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"bibr29-10600280231223737","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic lymphocytic leukemia\/small lymphocytic lymphoma (Version 1.2024). Accessed November 30, 2023. www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"bibr30-10600280231223737","doi-asserted-by":"publisher","DOI":"10.3324\/hematol.2022.281402"},{"key":"bibr31-10600280231223737","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2503"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231223737","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231223737","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231223737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:34Z","timestamp":1777374814000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231223737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/10600280231223737"],"URL":"https:\/\/doi.org\/10.1177\/10600280231223737","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}